Search Within

William Thomas Johnson

Formats
  1. Meeting Abstract (38)
  2. Journal Article (11)
  3. Research Letter (5)
  4. Review (2)
Groups
  1. Hematologic Malignancies, Division of (56)
  2. Center for Hematologic Malignancies (48)
  3. Department of Medicine (48)
  4. Lymphoma (47)
  5. Population Sciences Research Program (45)
  6. Hematology-Oncology Fellows (41)

More Groups

People
  1. Steven Horwitz (45)
  2. Alison Moskowitz (43)
  3. Gilles Salles (34)
  4. Lorenzo Falchi (34)
  5. Santosha Vardhana (34)
  6. Zachary Epstein-Peterson (34)

More People

Years
  1. 2025 (7)
  2. 2024 (17)
  3. 2023 (18)
  4. 2022 (7)
  5. 2021 (7)
Publications
  1. Blood (36)
  2. Blood Advances (4)
  3. Haematologica (2)
  4. Hematological Oncology (2)
  5. Journal of Clinical Oncology (2)
  6. Leukemia and Lymphoma (2)

More Publications

Publishers
  1. American Society of Hematology (40)
  2. Elsevier Inc. (3)
  3. Wiley Blackwell (3)
  4. American Society of Clinical Oncology (2)
  5. Ferrata Storti Foundation (2)
  6. Taylor & Francis Group (2)

More Publishers

Results (56)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficient targeting of CD38 in mature T-cell neoplasms with daratumumab and allogeneic NK cells
    Meeting Abstract

    Johnson, W. T.; Isabelle, C.; Vogel, A. N.; Brammer, J. E.; Boles, A. E.; McConnell, K.; Berge, R.; Nisenfeld, L.; Uppal, G.; Gong, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • TP53 mutations identify high-risk peripheral T-cell lymphoma patients treated with CHOP-based chemotherapy
    Meeting Abstract

    Johnson, W. T.; Ganesan, N.; Epstein-Peterson, Z. D.; Maccaro, C.; Galasso, N.; Sauter, C. S.; Neuman, R.; Khan, N.; Moskowitz, A. J.; Dogan, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Impact of choice of platinum-based salvage therapy on CNS relapse in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Buege, M. J.; Dao, P.; Dematteo, R. G.; LeVoir, A.; Pak, T.; Batlevi, C. L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Durable response to brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (BV-CHP) in a patient with CD30-positive PTCL arising as a post-transplant lymphoproliferative disorder (PTLD)
    Journal Article

    Hong, J.; Johnson, W. T.; Kartan, S.; Gonsalves, A. S.; Fenkel, J. M.; Gong, J. Z.; Porcu, P.
    Current Oncology (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of black patients with mycosis fungoides and Sézary syndrome: A subgroup analysis of the phase III MAVORIC trial
    Journal Article

    Johnson, W. T.; Kartan, S.; Sokol, K.; Nikbakht, N.; Porcu, P.
    Leukemia and Lymphoma (2021)

    Fulltext@MSK | Save